Tirzepatide vs Retatrutide

Both of these molecules are part of the same modern wave of multi-receptor incretin agonists, and the comparison most readers come here to make is whether the third receptor in retatrutide is worth the not-yet-approved status. Tirzepatide is approved, real-world-validated, and has the SURMOUNT trial set behind it; retatrutide's phase-2 data are striking but still preliminary, and the molecule is not yet on the same prescribing pathway in most regions.

Receptor coverage is the headline structural difference. Tirzepatide hits GLP-1 and GIP. Retatrutide adds glucagon agonism on top of those two. Glucagon's role here is not the textbook blood-sugar role — at low chronic exposure it appears to drive energy expenditure and influence hepatic lipid handling, which is the mechanism the trial designers were betting would push weight-loss numbers higher. The early data say it did, but the long-tail safety picture is still being filled in.

Cadence is the same on both: weekly subcutaneous administration. The titration ramp is where logs diverge. Tirzepatide moves through 2.5, 5, 7.5, 10, 12.5, 15 mg in the standard schedule, with the lower steps focused on gut tolerance. Retatrutide's published trial schedule moves in larger increments and ends at higher absolute doses; the unit-math calculator linked below handles the conversion once your vial concentration is set, but the two molecules cannot share the same reconstitution shortcut without re-running the math.

For tracking purposes the two molecules log very similarly — one shot per week, weight and waist measured at the same cadence, appetite and gut-tolerance scored daily during titration. The difference shows up in the long-tail data: tirzepatide has years of post-marketing observation now, retatrutide has trial data and a much smaller off-label cohort. The right molecule for any individual reader is a clinical conversation, not a side-by-side table call.

One more thing worth flagging for anyone logging either of these over a multi-month window: the published trial schedules assume a steady weekly cadence with no skipped doses, and the weight-loss numbers reported in SURMOUNT and the retatrutide phase-2 readout reflect that. Real-world logs almost never look that clean. Tirzepatide's longer post-marketing tail means there is more written guidance on what a missed dose, a delayed titration step, or a vial that was warmed too many times does to the trajectory. Retatrutide does not yet have that body of practical edge-case writing — the molecule is new enough that most off-label users are filling in those gaps for themselves in private logs. Either way, the calculator pages linked below are the place to plug in your actual vial size and dose, since the example numbers on this page only reflect the most common research-supplier configurations and will not match every reader's setup.